Isoform-specific radiotracers could distinguish epithelial FGFR2-IIIb from mesenchymal FGFR2-IIIc isoforms, or identify truncated decoy receptors, thereby refining tumor classification, revealing spatial heterogeneity, and guiding therapeutic decisions. Here, FGFR2 is linked to neoplasm.